Phaseline

Companies › Beijing Tide Pharmaceutical

Beijing Tide Pharmaceutical: clinical trials, targets and expected readouts

5 active drug programs in 10 registered trials: 5 Phase 1, 3 Phase 2, 2 Phase 3; Other, Oncology, Respiratory; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TDI01 suspension–Phase 3Idiopathic Pulmonary Fibrosis (IPF); GVHD, ChronicAug 2027
TRD205 Tablets–Phase 2Postoperative Analgesia After Unilateral Hip Arthroplasty–
TCC1727 tablet
KRAS inhibitor
–Phase 1Patients with Advanced Solid Tumors; Solid CancersSep 2028
benmelstobart–Phase 1Solid Cancers; Non-Clear Cell Renal Cell Carcinoma; Natural Killer T-cell Lymphoma; Non-Small Cell Lung CancerSep 2028
CPD704 Inhalation Suspension–Phase 1Healthy–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05970016TCC1727 tabletPhase 1Patients with Advanced Solid TumorsOncologyJul 2025
NCT07301203CPD704 Inhalation SuspensionPhase 1HealthyOtherJun 2026
NCT07543796TRD205 TabletsPhase 2Postoperative Analgesia After Unilateral Hip ArthroplastyOtherJun 2026
NCT06733051benmelstobartPhase 2Natural Killer T-cell LymphomaOncologyDec 2026
NCT07881900benmelstobartPhase 3Non-Clear Cell Renal Cell CarcinomaOncologyJun 2027
NCT06528847benmelstobartPhase 2Non-Small Cell Lung CancerOncologyJun 2027
NCT06169722TDI01 suspensionPhase 1GVHD, ChronicRespiratoryAug 2027
NCT07371663TCC1727 tabletPhase 1Solid CancersOncologySep 2028
NCT07371663benmelstobartPhase 1Solid CancersOncologySep 2028
NCT07464912TDI01 suspensionPhase 3Idiopathic Pulmonary Fibrosis (IPF)RespiratoryJul 2029

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Haihe Biopharma Shanghai Huaota Biopharmaceutical J-Pharma Ranok Therapeutics (Hangzhou) Monte Rosa Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.